<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CF330551-105A-4A80-AC95-14BE0FC2A606"><gtr:id>CF330551-105A-4A80-AC95-14BE0FC2A606</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Atherton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/65E193AC-4452-4D9A-98C1-2D5AF842FECA"><gtr:id>65E193AC-4452-4D9A-98C1-2D5AF842FECA</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Avery</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B6A16631-62FE-412A-AEAB-D3311E58ED1D"><gtr:id>B6A16631-62FE-412A-AEAB-D3311E58ED1D</gtr:id><gtr:firstName>Julia</gtr:firstName><gtr:surname>Hippisley-Cox</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1821300E-7166-4559-A2D5-46961B4F109A"><gtr:id>1821300E-7166-4559-A2D5-46961B4F109A</gtr:id><gtr:firstName>Denise</gtr:firstName><gtr:surname>Kendrick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/48ED4B90-9A10-4995-9602-13C629870E53"><gtr:id>48ED4B90-9A10-4995-9602-13C629870E53</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Hawkey</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3AA1D0DA-AE7C-4421-826F-02FCC2741E1E"><gtr:id>3AA1D0DA-AE7C-4421-826F-02FCC2741E1E</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Logan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F85797AB-F48E-4BF5-BB06-C7F59AF453B7"><gtr:id>F85797AB-F48E-4BF5-BB06-C7F59AF453B7</gtr:id><gtr:firstName>Carol</gtr:firstName><gtr:surname>Coupland</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700648"><gtr:id>C94445CF-D247-44B1-8865-555140193476</gtr:id><gtr:title>H. pylori Eradication vs Aspirin Toxicity (HEAT) Trial: Pilot Study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700648</gtr:grantReference><gtr:abstractText>The protocol has been drawn up with the help of the primary care research users group in Nottingham. Representatives will sit on the project advisory board, help with all patient information and communication documents, provide advice on how best to contact applicants and advice on the use of the media for recruitment and publicity. They have been centrally involved in the development of our research plans. The study will depend upon high level media publicity for success and this group will help us with this aspect of the subject and with using the links that are consequently developed to publicise results of the research when the trial is complete.</gtr:abstractText><gtr:technicalSummary>The proposed trial 
Substantive trial: Consenting aspirin users 60, identified by MIQUEST automated searching will undergo H. pylori breath testing and randomisation, if positive, to eradication immediately or after 18 months delay. Rates of ulcer bleeding over the first and second 18 month period will be assessed using primary (MIQUEST) and secondary care records and NHS Central Registry (deaths). Outcomes, confirmed by an adjudication committee, will be compared for the two randomised groups and for non-randomised H. pylori negative participants. 
Pilot Study: Rates of aspirin use and ulcer bleeding in potential collaborating areas will be established using the QResearch Database. Direct study in these areas will also investigate aspirin use as well as H. pylori infection in aspirin users, the success of eradication treatment and evaluate the feasibility of study methods.</gtr:technicalSummary><gtr:fund><gtr:end>2008-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>74584</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF289796-3ABB-4C00-87FF-EBCA4182CAF1"><gtr:id>DF289796-3ABB-4C00-87FF-EBCA4182CAF1</gtr:id><gtr:title>408 Increased Aspirin Use and Upper Gastrointestinal Bleeding Rates in Socially Deprived Patients</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f23527fb6d2b50f5404a823e8b0bb110"><gtr:id>f23527fb6d2b50f5404a823e8b0bb110</gtr:id><gtr:otherNames>Vinogradova Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4DD60039-E5F8-45DE-8CF3-54EA5CF97729"><gtr:id>4DD60039-E5F8-45DE-8CF3-54EA5CF97729</gtr:id><gtr:title>DIAGNOSTIC PRECISION OF PRIMARY CARE ELECTRONIC DATABASE FOR STUDY OF GASTROINTESTINAL BLEEDING AND ITS ABILITY TO DETECT THE INFLUENCE OF ASPIRIN</gtr:title><gtr:parentPublicationTitle>GUT</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/36a979e76efcaed377c3f6640a74f347"><gtr:id>36a979e76efcaed377c3f6640a74f347</gtr:id><gtr:otherNames>Leighton M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700648</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>